Findings

What do systematic reviews say?

5 questions · 5 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 20%High 4 · 80%

Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin

Overall survival (OS) · first‐line treatment of ovarian cancer

Weekly paclitaxel plus carboplatin showed no clear difference in overall survival (OS) compared with tri‐weekly paclitaxel plus carboplatin (high certainty).

1 finding from 1 review

Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
HR 0.92 [0.79, 1.06]
4 studies · 3699 participants
High

Carboplatin vs cisplatin chemotherapy

Overall survival (baseline risks for low‐ and high‐risk groups in the control arm were estimated at 1 year) · combination with third‐generation drugs for advanced non‐small cell lung cancer

Carboplatin showed no clear difference in overall survival (baseline risks for low‐ and high‐risk groups in… compared with cisplatin chemotherapy (high certainty).

1 finding from 1 review

Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer 2020 · Cochrane Headline outcomes only
HR 0.99 [0.82, 1.2]
10 studies · 2515 participants
High

Topotecon+Carboplatin+Paclitaxel vs Carboplatin+Paclitaxel

Overall Survivalclinical observation · patients with ovarian cancer

Topotecon+Carboplatin+Paclitaxel showed no clear difference in overall Survivalclinical observation compared with carboplatin+Paclitaxel (high certainty).

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
HR 1.02 [0.97, 1.06]
2 studies · 1998 participants
High

Gefitinib vs tri‐weekly paclitaxel plus carboplatin

Overall survival · EGFR M+ patients with NSCLC

Gefitinib showed no clear difference in overall survival compared with paclitaxel + carboplatin (high certainty).

1 finding from 1 review

First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell… 2021 · Cochrane Headline outcomes only
HR 0.95 [0.77, 1.18]
2 studies · 489 participants
High

Gefitinib vs pemetrexed + carboplatin with pemetrexed maintenance

Overall survival · EGFR M+ patients with NSCLC

Gefitinib showed no clear difference in overall survival compared with pemetrexed + carboplatin with pemetrexed maintenance (moderate certainty).

1 finding from 1 review

First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell… 2021 · Cochrane Headline outcomes only
HR 0.84 [0.63, 1.11]
2 studies · 371 participants
Moderate